162 related articles for article (PubMed ID: 37712677)
1. Assessing the utility of molecular diagnostic classification for cancers of unknown primary.
Moore EC; Blobe GC; DeVito NC; Hanks BA; Harrison MR; Hoimes CJ; Jia J; Morse MA; Jayaprakasan P; MacKelfresh A; Mulder H; Hockenberry AJ; Zander A; Stumpe MC; Michuda J; Beauchamp KA; Perakslis E; Taxter T; George DJ
Cancer Med; 2023 Oct; 12(19):19394-19405. PubMed ID: 37712677
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic challenges of patients with carcinoma of unknown primary.
Rassy E; Pavlidis N
Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
[TBL] [Abstract][Full Text] [Related]
3. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
4. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
[TBL] [Abstract][Full Text] [Related]
5. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
[TBL] [Abstract][Full Text] [Related]
6. A second-generation microRNA-based assay for diagnosing tumor tissue origin.
Meiri E; Mueller WC; Rosenwald S; Zepeniuk M; Klinke E; Edmonston TB; Werner M; Lass U; Barshack I; Feinmesser M; Huszar M; Fogt F; Ashkenazi K; Sanden M; Goren E; Dromi N; Zion O; Burnstein I; Chajut A; Spector Y; Aharonov R
Oncologist; 2012; 17(6):801-12. PubMed ID: 22618571
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
[TBL] [Abstract][Full Text] [Related]
10. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
[TBL] [Abstract][Full Text] [Related]
12. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
13. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
14. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
Greco FA; Hainsworth JD
Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma of unknown primary (CUP): an update for histopathologists.
Beauchamp K; Moran B; O'Brien T; Brennan D; Crown J; Sheahan K; Cotter MB
Cancer Metastasis Rev; 2023 Dec; 42(4):1189-1200. PubMed ID: 37394540
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
[TBL] [Abstract][Full Text] [Related]
18. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract][Full Text] [Related]
19. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.
Moon I; LoPiccolo J; Baca SC; Sholl LM; Kehl KL; Hassett MJ; Liu D; Schrag D; Gusev A
Nat Med; 2023 Aug; 29(8):2057-2067. PubMed ID: 37550415
[TBL] [Abstract][Full Text] [Related]
20. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
